Julie Wolf
Partner @ 2048 Ventures
New York, United States
Julie Wolf is a Partner at 2048 Ventures. Prior to 2048 Ventures, Julie was at SOSV's IndieBio New York office, where she was the Chief Science Officer. Before IndieBio, Julie spent five years at the American Society for Microbiology, working with scientists to curate and communicate their discoveries. She was co-founder of Brooklyn Bio, abiotech startup creating improved microbial strains.Julie holds a Ph.D. in Microbiology, Immunology, and Cancer Biology from the University of Minnesota and did her postdoctoral fellowship at Albert Einstein College of Medicine.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 77%
Last updated:
For AI agents: llms.txt
Industries Julie Wolf invests in
Stages Julie Wolf invests in
Countries Julie Wolf invests in
Investment Focus
Industry
- Health Care 8 (36%)
- Biotechnology 7 (32%)
- Artificial Intelligence 6 (27%)
- Life Science 5 (23%)
- Medical 3 (14%)
Stage
- Pre-Seed 11 (50%)
- Seed 9 (41%)
Country
- United States 12 (55%)
- United Kingdom 2 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Century Health
|
Century Health accelerates drug development and commercialization by applying AI to real-world data. It is far too slow today to answer critical questions because the richest clinical data is locked away in silos. Our platform does the heavy lifting to rapidly get you the insight you need, all while supporting the research community and protectingpatient privacy. | $5M / Seed / May 19, 2026 | |
Pocket
|
Pocket is an AI powered front office that operates system for medical clinics. | $1.4M / Pre-Seed / Mar 30, 2026 | |
|
Nionyx Bio
|
Nionyx Bio builds AAV-based gene therapies to address some of the most potent kidney genetic diseases. | $4M / Seed / Sep 29, 2025 | |
|
Kascaid
|
Kascaid is developing biosensors for real-time monitoring of inflammatory biomarkers. | $2.3M / Pre-Seed / Jun 09, 2025 | |
Nimbus Health
|
Our mission is to redefine the standard of care in pulmonary medicine and deliver the best lung care in America. We’re rebuilding the pulmonary clinic around a technology platform and a set of virtual and physical interventions calibrated to keep lung conditions under control. At a Nimbus Clinic, rich patient data and predictive models allow ourproviders to make more thoughtful medical decisions, and step in at exactly the right moment. | $12M / Seed / May 13, 2025 | |
Humane Genomics
|
Humane Genomics is a virus development platform that develops artificial viruses to cure diseases. The company was founded in 2019 and is headquartered in New York, United States. | $4M / Seed / Feb 12, 2025 | |
TwoStep Therapeutics
|
TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors. | $6.5M / Seed / Jun 25, 2024 | |
Tetsuwan Scientific
|
Pioneering the development of AI agents capable of wet lab experimentation. | $2.7M / Pre-Seed / Apr 18, 2024 | |
|
Century Health
|
Century Health accelerates drug development and commercialization by applying AI to real-world data. It is far too slow today to answer critical questions because the richest clinical data is locked away in silos. Our platform does the heavy lifting to rapidly get you the insight you need, all while supporting the research community and protectingpatient privacy. | $2M / Pre-Seed / Mar 27, 2024 | |
Neobe Therapeutics
|
Neobe Therapeutics provides immunotherapies, clinical trials, research, and tumor-colonizing bacteria engineering services. | $2.3M / Seed / Feb 29, 2024 | |
| See all 22 investments → | |||
Co-Investors
Everywhere Ventures
6 deals together
Alumni Ventures
5 deals together
25madison
2 deals together
Gaingels
2 deals together
InnovateHealth Ventures
2 deals together
LifeX Ventures
2 deals together
About 2048 Ventures
We back visionary founders who are building technologies of the future.2048 Ventures is a thesis-driven earliest stage venture capital firm. We are founders, experienced operators, nerds and dreamers obsessed with the future. We've backed over 200 startups and have the experience and conviction to lead your pre-seed or seed round.We getyou and your vision before others.We are systems thinkers, engineers, and product junkies. We think about the future non-stop and are ready to understand and back you before anyone else. When we decide to invest, we write you a check and then help you close the rest of the round. We lead rounds with high conviction, and write $500K - $2M checks.
2048 Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Iskold
Founder & Partner
|
|||
|
Julie Wolf
Partner
|
|||
Leonard Wossnig
Venture Network Partner
|
|||
Minda Brusse
Venture Partner
|
|||
Rachel Lyubovitzky
Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Julie Wolf invest in?
Julie Wolf invests primarily in Health Care, Biotechnology and Artificial Intelligence startups, most often at Pre-Seed and Seed stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Julie Wolf last invest?
The most recent investment recorded for Julie Wolf closed in May 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
